As Taliban Rule Enters Sixth Year, Healthcare For Afghan Women Is Being Dismantled - Health Policy Watch

MontrealThe dismantling of the nine-storey building and facade will begin on Oct. 19. Owners are asking members of the public to avoid the area during the operation. Dismantling of 9-storey building and facade to begin Oct. 19CBC News · Posted: Oct 15, 2026 11:22 AM EDT | Last Updated: October 15Listen to this articleEstimated 2 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. The former Canada Malting plant is an iconic landmark in the Sud-Ouest borough of Montreal. (Wikimedia Commons)The owners of the Canada Malting plant in the Sud-Ouest borough say the site will soon be partially dismantled in response to collapse risks highlighted in a recent engineering report. The report, released earlier this month, found the structure represented an "imminent danger" to public safety. One of the biggest risks was deemed to be a brick facade wall that engineers warned is “hanging by a thread" after having detached from the roof, prompting concerns it could collapse onto St-Ambroise Street, potentially injuring pedestrians and damaging parked vehicles.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.